Curriculum Vitae Susan Jones Kalota, M.D. License

1 Curriculum Vitae Susan Jones Kalota, License Arizona Medical License : 20774. Education 1975 - 1980 University of California San Diego in Biology 1977 - 1978 Education Abroad Program: Pau & Paris, France 1982 - 1986 Howard University College of Medicine: Washington, 1986 - 1988 University of California San Diego Surgery Internship 1988 - 1992 University of California San Diego Urology Residency 10/1990 Observer at Institute of Urology London, England Publications Parsons, , Boychuk, D., Jones , , Hurst, R. and Callahan, H. Bladder surface glycosaminoglycans: an epithelialpermeability barrier. JUrol 143: 139-142. 1990. Jones , , Parsons, and Stein, P. Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 143(4): 280A 1990.

2 Jones , , Stein, and Parsons, - Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 148(1) 163 166 1990. Jones , The Injured Bladder AUA Today. Jones , , Greene, and Parsons, Evaluation of the urologic patient. The Practice of Urology Norton & Co. New York, NY 1992. Bidar, M., Kalota, and Kaplan, Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? JUrol 150(1) 153-155. Stratasis Small Intestinal Submucosa Tension-Free Sling Case Report JUro 172(4): 1349 1350 October 2004. Presentations Jones , and Parson, Prevention of acrolein-induced bladder injury pentosanpolysulfate. AUA 85th Annual Meeting. New Orleans, LA May 1990. Jones , The in's and out's of GU Bleeding, Presented to Southern California Chapter of the American Urologic Association Allied.

3 San Diego, CA September 1991. Speaker for Pfizer, Bayer and Ortho-McNeil Alza Pharmaceutical Speaker's Bureau 1999 2001. Nurse Practitioners Annual Convention - San Diego, CA 2000. Private Practice Gynecologist on simple cystitis - San Francisco, CA 2000. Multiple Community Presentations for Physicians and Lay Persons Consortium of Multiple Sclerosis Centers- Atlanta, GA 2009. Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient Consortium of Multiple Sclerosis Centers- San Antonio, TX 2010. Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient Awards and Honors 1982 - 1984 Academic Achievement Award for academic excellence at Howard University Medical School 1985 Nomination to AOA Medical Honor Society of Gamma Chapter of AOA.

4 1986 American Medical Women's Association Scholarship Achievement Citation 1986 Department of Surgery honorable mention for scholastic achievement 1986 Department of Medicine honorable mention for scholastic achievement 1986 Ralph C. Kennedy, Award for highest score in Psychiatry on National Board Exam 1986 Merck Manual Award for highest scholastic records Research Experience Federal Drug Administration Gastroenterology and Urology Devices Panel Member - Center for Devices & Radiological Health (CDRH) Office of Device Evaluation (ODE) Division of Reproductive, Abdominal and Radiological Devices (DRARD) Gastroenterology and Renal Devices Branch (GRDB) 2004 - 2008. Stress incontinence , Study Phase 2, 1998. Urge incontinence , Study Phase 3B, 8 patients enrolled/27 months long, 1999.

5 Quality of Life Study for Overactive Bladder Phase 4, 18 patients enrolled 8 weeks long. Pharmacia/Upjohn, 2001. Overactive Bladder Study Phase 3B, 6 patients enrolled/12 weeks long/Pharmacia/Upjohn, 2001. Urogenital Symptoms in Post Menopausal Women Study Phase 4, 2001. Phase 4 Overactive Bladder/Pfizer/PPD with Rapid Trials, 2004. Sanofi-Synthelabo BPH Registry, 22 patients enrolled, 2004. Watson Quality of Life Study for Oxytrol in OAB 2004, 33 patients enrolled, 2004. Phase 3/AstraZeneca/ Jupiter/LDL and C-Reaction Protein/Cholesterol, 2004. Pharmatech/ Phase 3/ Advanced Prostate Cancer, 2004. Odyssey Pharmaceuticals/ Phase 4/ Overactive Bladder, 2005. AstraZeneca/ Overactive Bladder/ Phase 3, 2005. Nymox/ Phase 2/ Benign Prostatic Hyperplasia, 2005.

6 Praecis/ INC Research/Prostate Cancer/ Phase 3, 2005. Indevus/ Double-Blind and Open-Label Drug for OAB, 2005. Pfizer/Phase 2/Stress incontinence / 2006. Astellas/ Phase 4/OAB pts with Sx's of BPH/2006. Nymox/ Phase2/ Benign Prostatic hypertrophy/2007. Astellas/ Phase 2/ Male subjects with LUTS and BOO/2007. Solace Therapeutics/An evaluation of the AttnueX Intravesical System in the Management of Female Patients with Stress urinary incontinence /2007. AMS/The Prolapse Registry: An Observational Collection of Short- and Long- Term Patient Outcomes Following Use of AMS Surgical Devices for the Repair Of Female Genital Astellas /047 Phase III Double Blind Placebo Controlled/ OAB Study /2008. Astellas/ 049 Phase III Double Blind Placebo Controlled / OAB Study/2008.

7 Uroplasty/ Study of Urgent PC Vs. Sham Effectiveness in Treatment of OAB/. 2008. Astellas/074 Phase III Double Blind, Parallel Group, Placebo Controlled/ OAB. Study/2009. Nymox/ Phase III Randomized Parallel-Group Placebo Controlled, Double Blind Clinical Evaluation/Treatment of BPH/2009. Pfizer/ 13 Week Single Arm, Open Label, Multicenter Study to Evaluate Refill Adherence And Satisfaction with Fesoterodine Plus Your Way Patient Support Plan in Patients with Symptoms of OAB/2009. Allergan 191622-095/A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX. (Botulinum Toxin A) Purified Neurotoxin Complex Followed by a Treatment With Botox as Applicable in Patients with Idiopathic Overactive Bladder and urinary incontinence .

8 Allergan A Multicenter, Long-Term Follow-up Study of Safety and Efficacy of the Safety and Efficacy of Botox (Botulinum Toxin Type-A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder and urinary incontinence . Ferring (FE 200486)/ A Randomized, Parallel Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection, In Terms Of Prostate Size Reduction In Prostate Cancer Patients Of Intermediate . To- High Risk, Who Require Neoadjuvant Hormone Therapy Prior To Radioactivity (Curative Intent). Endo (EN3348-303)/ A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of EN3348 (MCC) As Compared With Mitomycin C In The Intravesical Treatment Of Subjects With BCG Recurrent Or Refractory Non-Muscle Invasive Bladder Cancer.

9 Pfizer A0221049/ A 12 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. Ethicon Endo Surgery, Inc (CI-10-0009) Multi-center, prospective, randomized, double-blind, sham-controlled clinical study to evaluate safety and effectiveness of a transcutaneous, high-frequency, amplitude-modulated, non-invasive neuromodulation device on urgency urinary incontinence in subjects with overactive bladder (OAB). Professional Affiliations 12/2001 Recertification - Diplomate American Board of Urology Southern Arizona Urologic Society Member 1992 present President 1994. Secretary 1993. Arizona Urologic Society member 1992 present Western Section of American Urologic Association member 1992 present American Urologic Association member 1988 present Health Policy Committee 1999 2000.

10 Committee on Women's Issues in Urology 1999 2000. Society of Woman in Urology 1992 present President 1999 2000. President-elect 1998 1999. Board of Directors 1997 1998. Tucson Society of Woman Physicians 1993 - present President 2002, 2011. Founding President 1993 1994. Secretary/Treasurer 1994 present Pima County Medical Society 1992 present Secretary/Treasurer 2001. Board of Directors 1999 2001. Board of Directors 1996 1998. Arizona Medical Association 1999 present ArMA Committee on Insurance Reform 1999 2000. Scientific Advisory Board for Novasys Medical Practice Experience 04/2011- present Group Practice General Urology- Urological Associates of Southern Arizona, Tucson, AZ. 8/1992 04/2011 Private Practice General Urology- Arizona Urologic Specialists, Tucson, AZ.